Why Some Patients Are Prescribed Mounjaro and Others Are Not
Not every patient who asks about Mounjaro will be prescribed it. In Singapore, Mounjaro is a prescription-only medicine with specific approved indications, and doctors are expected to decide suitability based on medical need, safety, and whether the treatment can be appropriately supervised. That means prescribing is not based on patient interest alone. It depends on whether the person fits the clinical indication, whether the benefit-risk balance is reasonable, and whether follow-up can be done safely.
Key Takeaways
Some patients are prescribed Mounjaro because they meet approved medical criteria for type 2 diabetes treatment or weight management.
Other patients are not prescribed it because they may fall outside the approved indication, have a risk profile that needs more caution, or need a different treatment plan first.
Singapore doctors assess more than body weight alone. They usually review BMI, comorbidities, medicines, side effects, and whether the patient can be monitored properly.
In Singapore, telemedicine prescribing still requires proper clinical assessment, and MOH has specifically highlighted lapses such as issuing prescriptions without proper assessment or not conducting video consultations for first-time patients.
Mounjaro should be understood as part of doctor-supervised obesity or diabetes care, not as a routine consumer weight-loss request.
Why suitability is not the same for every patient
Doctors do not assess Mounjaro in a one-size-fits-all way. Two patients may both want weight loss, but one may meet the medical indication while the other does not. Another patient may technically meet BMI criteria but still need extra caution because of current medicines, adverse-effect risk, or the need for closer review. This is consistent with Singapore’s obesity guidance, which frames treatment as a clinical process involving lifestyle, behavioural, medical, and sometimes surgical approaches rather than a single automatic pathway.
The starting point is the approved indication. HSA’s June 2025 approval update states that Mounjaro is indicated for adults with insufficiently controlled type 2 diabetes mellitus, and also for weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of at least 30 kg/m², or at least 27 kg/m² with at least one weight-related comorbid condition.
When a patient is more likely to be prescribed Mounjaro
They meet the approved indication
One reason some patients are prescribed Mounjaro is that they fit the indication clearly. For weight management in Singapore, that generally means obesity, or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus. For other patients, the discussion may be within the diabetes indication instead.
This matters because doctors are not meant to prescribe purely on the basis of a desire to be slimmer. The approved role is medical and risk-based. Patients who are more likely to be prescribed Mounjaro are usually those whose weight or metabolic status is already relevant to current or future health risk.
They have weight-related or metabolic health risks
Doctors also look at whether excess weight is part of a broader health pattern. Singapore public-health guidance notes that, in Asian populations, BMI 23.0 to 27.4 kg/m² is associated with moderate risk and BMI 27.5 kg/m² and above with high risk for weight-related health problems such as type 2 diabetes, high blood pressure, heart disease, stroke, some cancers, and bone and joint disorders.
That does not mean every patient in those ranges will receive medication. It does mean that doctors often assess weight in the context of cardiometabolic risk rather than appearance alone. A patient with obesity, prediabetes, hypertension, and repeated difficulty maintaining weight loss may be viewed very differently from a patient whose interest is mainly cosmetic. This is an inference drawn from HSA’s indication language together with Singapore’s obesity-risk framework.
They are suitable for monitored treatment
A patient is more likely to be prescribed Mounjaro when the doctor believes follow-up can be done properly. Singapore’s obesity guidelines describe weight management as a structured process that includes weight loss and weight maintenance, not just initial intervention. MOH has also stressed that telemedicine should not bypass proper assessment.
In practical terms, this means the doctor may be more comfortable prescribing when there is a clear diagnosis, adequate baseline history, and a realistic follow-up plan for dose progression, tolerability, and review.
Why some patients are not prescribed Mounjaro
They do not meet the current medical criteria
Some patients are not prescribed Mounjaro simply because they do not fall within the approved indication. A person may want treatment for minor weight reduction, but if the clinical threshold is not met, a doctor may decide that medication is not appropriate. HSA’s current indication is tied to defined diabetes use or BMI-based weight-management criteria with comorbidity requirements where relevant.
This is one of the main reasons two patients can receive different answers. The question is not just whether they want the same medicine, but whether the same medical indication applies to both.
Their risk profile needs more caution
Another reason some patients are not prescribed Mounjaro is that the safety picture may be less straightforward. HSA’s benefit-risk summary notes common adverse reactions such as nausea, diarrhoea, decreased appetite, vomiting, dyspepsia, and constipation. It also discusses issues such as hypoglycaemia risk when used with insulin secretagogues or insulin, hypersensitivity reactions, injection-site reactions, acute gallbladder disease, and increases in pancreatic enzymes.
That does not automatically rule treatment out, but it does mean doctors may pause, investigate further, or choose another approach if the patient’s history suggests that initiation or monitoring will be more complicated.
Their current medicines or conditions make prescribing less straightforward
Suitability also depends on what else the patient is taking and how their underlying conditions are being managed. HSA’s summary report notes that when initiating Mounjaro, clinicians should consider reducing concomitant insulin secretagogues or insulin to reduce hypoglycaemia risk.
So a patient with a more complex diabetes regimen may still be prescribed Mounjaro, but only after more careful planning. Another patient may be deferred if the doctor thinks the immediate priority is stabilising existing treatment first. That is a clinical judgement issue rather than a simple yes-or-no product decision.
The consultation pathway is not adequate for safe first prescribing
Some patients are not prescribed during an initial teleconsult because the doctor decides the consultation is not sufficient for safe first-time prescribing. MOH has stated that common lapses in telemedicine investigations included doctors issuing prescriptions without proper clinical assessment and not conducting video consultations for first-time patients.
This means a patient may be told to attend an in-person consultation, provide more medical information, or complete further review before any prescribing decision is made. In a compliant Singapore setting, that is part of appropriate clinical gatekeeping.
What doctors usually assess before deciding
BMI and comorbidities
Doctors usually begin with baseline measurements and health context. BMI is one part of this, but the presence of comorbidities can be just as important. HSA’s approved weight-management indication specifically combines BMI with weight-related comorbidities in some patients, while Singapore guidance links higher BMI ranges with increasing health risk in Asian populations.
Medical history and treatment goals
Doctors also look at why treatment is being considered. Is the main issue insufficiently controlled type 2 diabetes, clinically significant obesity, obstructive sleep apnoea risk, prediabetes, or another metabolic concern? A patient whose goals align with recognised medical needs is more likely to fit the approved treatment pathway than someone seeking purely cosmetic change.
Tolerability and monitoring capacity
Even if a patient qualifies on paper, the doctor still needs to judge whether treatment is likely to be tolerable and monitorable. The known gastrointestinal adverse effects and other precautions in HSA’s assessment make follow-up important, especially during treatment initiation and dose escalation.
Why “not prescribed” does not always mean “not suitable forever”
A patient who is not prescribed Mounjaro at one point in time is not necessarily excluded permanently. Sometimes the answer is “not yet” rather than “never.” A doctor may first want lifestyle measures strengthened, baseline issues clarified, other medicines adjusted, or a more appropriate consultation format arranged. This fits Singapore’s broader clinical view of obesity management as staged and multidisciplinary rather than purely transactional.
In that sense, different prescribing decisions often reflect differences in timing, medical context, and supervision needs rather than unequal access alone.
How this article fits within the pillar topic
This cluster article explains one central part of the wider suitability question: why doctors do not give the same answer to every patient asking about Mounjaro. The variation usually comes from differences in approved indication, metabolic risk, current treatment complexity, safety considerations, and whether safe monitoring can be arranged under Singapore prescribing standards.
Takeaway
Some patients in Singapore are prescribed Mounjaro because they meet the approved medical indication and appear suitable for monitored treatment. Others are not prescribed it because they may not meet the BMI or comorbidity criteria, may have a more complex safety profile, or may need a different assessment pathway before treatment is considered. The key point is that doctors are deciding medical suitability, not simply responding to demand for a weight-loss medicine.
Because Mounjaro has clinically relevant side effects and precautions, and because Singapore regulators expect proper standards of assessment and prescribing for prescription-only medicines.
To see how eligibility, BMI thresholds, GLP-1–GIP treatment context, and doctor-led decision-making fit into the broader Singapore picture, you can refer to How Singapore Doctors Determine Suitability for Mounjaro Medication.
FAQ
Is BMI the only reason one patient gets prescribed Mounjaro and another does not?
No. BMI matters, but doctors also review comorbidities, diabetes status, current medicines, adverse-effect risk, and whether follow-up can be done safely.
Can someone be refused Mounjaro even if they want it for weight loss?
Yes. Wanting weight loss is not the same as meeting a medical indication. In Singapore, the approved weight-management indication is tied to BMI thresholds and, for some patients, at least one weight-related comorbid condition.
Why might a doctor delay prescribing instead of saying yes immediately?
A doctor may need more history, an in-person review, medication adjustment, or a safer monitoring plan first. MOH has explicitly said prescriptions should not be issued without proper clinical assessment, especially for first-time telemedicine patients.
Does having type 2 diabetes make prescribing more likely?
It can, because Mounjaro is indicated in Singapore for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy when metformin is inappropriate or in addition to other diabetes medicines. But suitability still depends on the individual clinical situation.